M M Javle

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi A phase II study of gemcitabine and capecitabine in advanced cholangiocarcinoma and carcinoma of the gallbladder: a single-institution prospective study
    Renuka V Iyer
    Department of Medical Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA
    Ann Surg Oncol 14:3202-9. 2007
  2. ncbi Reirradiation to the abdomen for gastrointestinal malignancies
    Waqar Haque
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Radiat Oncol 4:55. 2009
  3. ncbi Recent advances in gastrointestinal oncology--updates and insights from the 2009 annual meeting of the American society of clinical oncology
    Milind Javle
    Division of Medical Oncology and Hematology, Loma Linda University, Loma Linda, CA 92354, USA
    J Hematol Oncol 3:11. 2010
  4. ncbi Celecoxib and mucosal protection: translation from an animal model to a phase I clinical trial of celecoxib, irinotecan, and 5-fluorouracil
    Milind M Javle
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Institute, Houston, Texas 77030, USA
    Clin Cancer Res 13:965-71. 2007
  5. ncbi Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study
    M Javle
    Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
    Br J Cancer 100:1842-5. 2009
  6. ncbi Capecitabine, oxaliplatin and radiotherapy: a phase IB neoadjuvant study for esophageal cancer with gene expression analysis
    Milind M Javle
    Department of Gastrointestinal Medical Oncology, UT MD Anderson Cancer Institute, Houston, Texas, USA
    Cancer Invest 27:193-200. 2009
  7. ncbi Updates in Gastrointestinal Oncology - insights from the 2008 44th annual meeting of the American Society of Clinical Oncology
    Milind Javle
    Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Hematol Oncol 2:9. 2009
  8. ncbi Pilot study of gefitinib, oxaliplatin, and radiotherapy for esophageal adenocarcinoma: tissue effect predicts clinical response
    Milind Javle
    Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Am J Clin Oncol 31:329-34. 2008
  9. ncbi Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies
    Milind M Javle
    Department of Gastrointestinal Medical Oncology, UT M D Anderson Cancer Center, Houston, TX, USA
    BMC Cancer 10:368. 2010
  10. ncbi Epithelial-mesenchymal transition (EMT) and activated extracellular signal-regulated kinase (p-Erk) in surgically resected pancreatic cancer
    M M Javle
    Department of Gastrointestinal Medical Oncology, UT MD Anderson Cancer Center, Unit 426, 1515 Holcombe Ave, Houston, TX 77030, USA
    Ann Surg Oncol 14:3527-33. 2007

Collaborators

Detail Information

Publications39

  1. ncbi A phase II study of gemcitabine and capecitabine in advanced cholangiocarcinoma and carcinoma of the gallbladder: a single-institution prospective study
    Renuka V Iyer
    Department of Medical Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA
    Ann Surg Oncol 14:3202-9. 2007
    ..To determine the clinical benefit response (CBR), time to tumor progression (TTP), overall survival, and effect on quality of life (QOL) of gemcitabine and capecitabine in patients with advanced biliary cancer...
  2. ncbi Reirradiation to the abdomen for gastrointestinal malignancies
    Waqar Haque
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Radiat Oncol 4:55. 2009
    ..Our goal was to retrospectively determine rates of toxicity, freedom from local progression and overall survival in gastrointestinal cancer patients treated with reirradiation to the abdomen...
  3. ncbi Recent advances in gastrointestinal oncology--updates and insights from the 2009 annual meeting of the American society of clinical oncology
    Milind Javle
    Division of Medical Oncology and Hematology, Loma Linda University, Loma Linda, CA 92354, USA
    J Hematol Oncol 3:11. 2010
    ....
  4. ncbi Celecoxib and mucosal protection: translation from an animal model to a phase I clinical trial of celecoxib, irinotecan, and 5-fluorouracil
    Milind M Javle
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Institute, Houston, Texas 77030, USA
    Clin Cancer Res 13:965-71. 2007
    ..Cyclooxygenase-2 inhibitors may ameliorate chemotherapy-induced mucosal toxicity and enhance its antitumor effect. We investigated this hypothesis in the Ward colorectal cancer rat model and in a phase I clinical study...
  5. ncbi Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study
    M Javle
    Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
    Br J Cancer 100:1842-5. 2009
    ..8 and 9.8 months respectively. Grade 3 or 4 toxicities included neutropaenia (22%), thrombocytopaenia (14%), thromboembolic events (12%), hypertension (8%) and haemorrhage (6%)...
  6. ncbi Capecitabine, oxaliplatin and radiotherapy: a phase IB neoadjuvant study for esophageal cancer with gene expression analysis
    Milind M Javle
    Department of Gastrointestinal Medical Oncology, UT MD Anderson Cancer Institute, Houston, Texas, USA
    Cancer Invest 27:193-200. 2009
    ..To determine the maximal tolerated dose of capecitabine with oxaliplatin + radiotherapy in a phase I study of localized esophageal cancer...
  7. ncbi Updates in Gastrointestinal Oncology - insights from the 2008 44th annual meeting of the American Society of Clinical Oncology
    Milind Javle
    Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Hematol Oncol 2:9. 2009
    ..Sunitinib is also an active agent in hepatocellular carcinoma, and may represent an alterative to sorafenib for advanced disease. These and other important presentations from the 2008 ASCO annual meeting are discussed in this article...
  8. ncbi Pilot study of gefitinib, oxaliplatin, and radiotherapy for esophageal adenocarcinoma: tissue effect predicts clinical response
    Milind Javle
    Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Am J Clin Oncol 31:329-34. 2008
    ..We report here early results of a planned phase I/II study of gefitinib, oxaliplatin, and RT for locally advanced, unresectable esophageal cancer...
  9. ncbi Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies
    Milind M Javle
    Department of Gastrointestinal Medical Oncology, UT M D Anderson Cancer Center, Houston, TX, USA
    BMC Cancer 10:368. 2010
    ..The addition of erlotinib to rapamycin can down-regulate rapamycin-stimulated Akt and results in synergistic antitumor activity with erlotinib in preclinical tumor models...
  10. ncbi Epithelial-mesenchymal transition (EMT) and activated extracellular signal-regulated kinase (p-Erk) in surgically resected pancreatic cancer
    M M Javle
    Department of Gastrointestinal Medical Oncology, UT MD Anderson Cancer Center, Unit 426, 1515 Holcombe Ave, Houston, TX 77030, USA
    Ann Surg Oncol 14:3527-33. 2007
    ..We investigated the expression of EMT markers (low E-cadherin, high fibronectin, and vimentin) and their association with p-Erk in resected pancreatic cancer...
  11. ncbi Epidermal growth factor receptor-directed therapy in esophageal cancer
    A U Pande
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA
    Oncology 73:281-9. 2007
    ..Herein, we review the current literature on this subject...
  12. ncbi S-phase modulation by irinotecan: pilot studies in advanced solid tumors
    N Ramnath
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Cancer Chemother Pharmacol 56:447-54. 2005
    ..Lesser increases were seen with 40 and 60 mg/m(2). CPT-11 followed 24 h later by 5-FU 400 mg/m(2) per week for 4 weeks was well tolerated. In the study of CPT-11 followed by GEM 1000 mg/m(2), 60 mg/m(2) of CPT-11 was the MTD...
  13. ncbi Chemoradiation is a tolerable therapy for older adults with esophageal cancer
    Sujatha Nallapareddy
    Roswell Park Cancer Institute, Elm and Carlton Sts, Buffalo, NY 14263, USA
    Anticancer Res 25:3055-60. 2005
    ..The median survival of the patients was 10 months. CONCLUSION: CRT was tolerable for older patients with EC. Close monitoring for dehydration, nutritional compromise and pulmonary toxicity is required...
  14. ncbi Management of locoregional stage esophageal cancer: a single center experience
    M M Javle
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York 14263, USA
    Dis Esophagus 19:78-83. 2006
    ..001). Patients with locoregional esophageal cancer who are eligible for surgical resection either alone or as a part of multimodal therapy may have better outcomes than those treated with non-surgical approaches...
  15. ncbi Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer
    Motofumi Tanaka
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Cancer 116:5325-35. 2010
    ....
  16. ncbi Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma
    Manal M Hassan
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 116:1938-46. 2010
    ..This objective of the current study was to determine the association between HCC risk and diabetes duration and type of diabetes treatment...
  17. ncbi Cyclooxygenase-2 (COX-2) levels before and after chemotherapy: a study in rectal cancer
    Veena Watwe
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Am J Clin Oncol 28:560-4. 2005
    ..CONCLUSIONS: COX-2 induction was seen with CRT in this population of rectal cancer patients. Prognostic significance of this induction remains to be defined in a larger cohort...
  18. ncbi Epidermal growth factor receptor expression correlates with histologic grade in resected esophageal adenocarcinoma
    Neal W Wilkinson
    Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, New York, USA
    J Gastrointest Surg 8:448-53. 2004
    ..A trend toward improved disease-free and overall survival was seen in EGFR negative patients...
  19. ncbi Surgical resection after TNFerade therapy for locally advanced pancreatic cancer
    Manpreet K Chadha
    Department of Medicine, Roswell Park Cancer Institute and State University of New York at Buffalo, Buffalo, NY, USA
    JOP 10:535-8. 2009
    ..Transfection of tumor cells with TNFerade maximizes the antitumor effect of TNF-alpha under influence of radiation leading to synergistic effects in preclinical studies...
  20. ncbi Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity
    Taro Okazaki
    Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 16:320-9. 2010
    ....
  21. ncbi Insulin-like growth factor axis gene polymorphisms and clinical outcomes in pancreatic cancer
    Xiaoqun Dong
    Department of Gastrointestinal Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Gastroenterology 139:464-73, 473.e1-3. 2010
    ..We examined whether IGF-axis gene variants are associated with clinical outcomes in pancreatic cancer...
  22. ncbi Combined hepatocholangiocarcinoma: case-series and review of literature
    Vishal Bhagat
    Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
    Int J Gastrointest Cancer 37:27-34. 2006
    ..0357, one-sided exact log-rank test). CONCLUSIONS: Chronic inflammation and cirrhosis may play a role in pathogenesis of CHCC. Surgical resection and early stage at diagnosis predict longer survival...
  23. ncbi Palliation of malignant dysphagia in esophageal cancer: a literature-based review
    Milind Javle
    Roswell Park Cancer Institute and State University of New York at Buffalo, Buffalo, New York 14263, USA
    J Support Oncol 4:365-73, 379. 2006
    ..The benefits and disadvantages of these approaches along with a concise review of the literature are presented...
  24. ncbi Expression of intestinal trefoil factor (TFF-3) in hepatocellular carcinoma
    Thaer Khoury
    Department of Pathology, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
    Int J Gastrointest Cancer 35:171-7. 2005
    ..Intestinal trefoil peptide (TFF-3) expression has been demonstrated in benign hepatobiliary diseases, but there are limited data regarding its expression in HCC...
  25. ncbi Cisplatin and gemcitabine for small cell carcinoma of the gall bladder
    Sandeep Bahadur
    Department of Medicine, School of Medicine and Biomedical Sciences, State University New York, Buffalo, NY, USA
    Am J Clin Oncol 28:425-6. 2005
  26. ncbi Carcinoma of the esophagus with mixed basaloid squamous and glandular differentiation: a distinct histological presentation
    Vishal Bhagat
    Department of Medicine, State University of New York at Buffalo, Buffalo, NY, USA
    Int J Gastrointest Cancer 34:139-42. 2003
    ..We describe an unusual case report of esophageal BSCC with glandular differentiation. The clinical significance of glandular differentiation in this rare type of tumor is not known...
  27. ncbi Anaplastic pancreatic carcinoma. A case report and review of literature
    Manpreet K Chadha
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    JOP 5:512-5. 2004
    ..A brief review of the histological and radiological findings and the possible mechanisms of the pathogenesis of anaplastic tumors is included in the discussion...
  28. ncbi Phase I and pharmacokinetic study of weekly docetaxel, cisplatin, and daily capecitabine in patients with advanced solid tumors
    Marwan G Fakih
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Clin Cancer Res 11:5942-9. 2005
    ..Docetaxel, cisplatin, and capecitabine are three active chemotherapeutic agents with different mechanisms of action. This phase I study investigated the feasibility and pharmacokinetics of this combination given on a weekly schedule...
  29. ncbi Primary esophageal lymphoma: case series and review of the literature
    Krishdeep Singh Chadha
    Department of Internal Medicine, School of Medicine, State University of New York at Buffalo, Buffalo, New York 14263, USA
    Dig Dis Sci 51:77-83. 2006
  30. ncbi Regular aspirin use and esophageal cancer risk
    Vijayvel Jayaprakash
    Department of Epidemiology, Division of Cancer Prevention and Population Sciences, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
    Int J Cancer 119:202-7. 2006
    ..Overall, results from the current study suggest that regular aspirin use may be associated with reduced risk of esophageal cancer...
  31. ncbi Concurrent oxaliplatin, 5-fluorouracil, and radiotherapy in the treatment of locally advanced esophageal carcinoma
    Manpreet Kaur Chadha
    Department of Radiation Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA
    Cancer J 13:119-24. 2007
    ..We now report the efficacy data for 42 patients treated with this regimen...
  32. ncbi Activated Akt and Erk expression and survival after surgery in pancreatic carcinoma
    Krishdeep S Chadha
    Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, New York 14263, USA
    Ann Surg Oncol 13:933-9. 2006
    ..0433; HR, .4), p-Akt (P = .0002; HR, .2), and p-Erk (P = .0003; HR, 3.5) expression correlated significantly with survival. CONCLUSIONS: p-Erk and p-Akt expression may have prognostic and therapeutic implications in pancreatic cancer...
  33. ncbi Postoperative computed tomography scan surveillance for patients with stage II and III colorectal cancer: worthy of further study?
    Amir Mortazavi
    Department of Medicine, School of Medicine and Biomedical Sciences, State University of New York at Buffalo, Buffalo, New York, USA
    Am J Clin Oncol 28:30-5. 2005
    ..In conclusion, this retrospective study generates the hypothesis that CT surveillance may be of value. A prospective study, properly sized for power, is needed to answer this question...
  34. ncbi Risk factors associated with earlier age of onset in familial pancreatic carcinoma
    Ted A James
    Department of Surgical Oncology, Roswell Park Cancer Institute, Buffalo, New York 14263, USA
    Cancer 101:2722-6. 2004
    ..Smoking may play a significant role in the risk or promotion of pancreatic carcinoma in patients with an inherited predisposition...
  35. ncbi Neoadjuvant therapy for gastric cancer
    Manpreet K Chadha
    Department of Medicine, State University of New York, University at Buffalo, Erie County Medical Center, USA
    Oncology (Williston Park) 19:1219-27; discussion 1227-8, 1231-2. 2005
    ..This article provides a concise review of the literature on neoadjuvant therapy for gastric cancer and suggests avenues for further investigation...
  36. ncbi Gemcitabine and acute myocardial infarction--a case report
    Fadi M Bdair
    State University of New York at Buffalo, Buffalo, NY
    Angiology 57:367-71. 2006
    ..Ischemic complications of chemotherapeutic agents are discussed. A review of literature on this subject is presented. Gemcitabine should be administered with caution in patients with underlying cardiac disease...
  37. ncbi Akt expression may predict favorable prognosis in cholangiocarcinoma
    Milind M Javle
    Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York 14263, USA
    J Gastroenterol Hepatol 21:1744-51. 2006
    ..The aim of this clinicopathological study was to investigate the overexpression and co-expression of EGFR and related signaling proteins in cholangiocarcinoma and explore their relationship to clinical outcome...
  38. ncbi A phase I pharmacokinetic and pharmacodynamic study of s-3304, a novel matrix metalloproteinase inhibitor, in patients with advanced and refractory solid tumors
    Alberto A Chiappori
    H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
    Clin Cancer Res 13:2091-9. 2007
    ..S-3304 is a potent, orally active, noncytotoxic inhibitor of MMPs, primarily MMP-2 and MMP-9, that prolongs survival in mice xenografts and is well tolerated in healthy volunteers...
  39. ncbi Unusual locations of involvement by malignancies: Case 3. Gastric signet ring carcinoma presenting as a diffuse thigh mass
    Geetha N Varma
    Roswell Park Cancer Institute, Buffalo, NY, USA
    J Clin Oncol 21:3371-3. 2003